CervoMed Inc.: 10-Q filed 2026-05-15
What CervoMed Inc. reported in its quarterly report filed 2026-05-15 (fiscal Q1 2026): 28 published measures, 58 facts as tagged in accession 0001437749-26-017236.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2026-05-15
- Fiscal period
- fiscal Q1 2026
- Accession
- 0001437749-26-017236 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CervoMed Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 15,112,918 | USD | |
| At 2025-12-31 | 22,879,018 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 4,497,203 | USD | |
| At 2025-12-31 | 4,656,117 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 10,615,715 | USD | |
| At 2025-12-31 | 18,222,901 | USD | |
| At 2025-03-31 | 34,634,487 | USD | |
| At 2024-12-31 | 39,202,328 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 7,941,751 | USD | |
| At 2025-12-31 | 8,235,469 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -7,964,158 | USD | 90 |
| 2025-01-01 to 2025-03-31 | -4,894,034 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -8,018,338 | USD | 90 |
| 2025-01-01 to 2025-03-31 | -3,894,359 | USD | 90 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 0 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 1,917,491 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 13,800 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 0 | USD | 90 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 7,710,820 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 5,396,577 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | -105,662,009 | USD | |
| At 2025-12-31 | -97,697,851 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 9,258,319 | shares | 90 |
| 2025-01-01 to 2025-03-31 | 8,702,719 | shares | 90 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -0.86 | USD/shares | 90 |
| 2025-01-01 to 2025-03-31 | -0.56 | USD/shares | 90 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 349,196 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 361,167 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -8,110,524 | USD | 90 |
| 2025-01-01 to 2025-03-31 | -5,302,884 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 15,112,918 | USD | |
| At 2025-12-31 | 22,879,018 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 2,272,497 | USD | |
| At 2025-12-31 | 1,454,118 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 8,110,524 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 7,220,375 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 5,135,419 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 4,837,798 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 9,258,719 | shares | |
| At 2025-12-31 | 9,252,719 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 116,268,674 | USD | |
| At 2025-12-31 | 115,905,684 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | -208 | USD | |
| At 2025-12-31 | 5,816 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 1,695,341 | USD | |
| At 2025-12-31 | 1,267,005 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -7,970,182 | USD | 90 |
| 2025-01-01 to 2025-03-31 | -4,929,008 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 2,975,105 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 2,382,577 | USD | 90 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -1,021 | USD | 90 |
| 2025-01-01 to 2025-03-31 | -135 | USD | 90 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 146,366 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 408,850 | USD | 90 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -426,993 | USD | 90 |
| 2025-01-01 to 2025-03-31 | -625,004 | USD | 90 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 765,364 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 349,158 | USD | 90 |
Inspect the source
- Entity
- CervoMed Inc. / CIK 0001053691
- Captured
- 2026-09-20T05:17:36.273Z
- SEC response SHA-256
0a28d9e08b18175e4a16bd2486e9ebae9dc8a6e8a3f7e429c0f71f98175b0255
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001053691.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))